Camelid Single-Domain Antibodies: Promises and Challenges as Lifesaving Treatments

Since the discovery of camelid heavy-chain antibodies in 1993, there has been tremendous excitement for these antibody domains (VHHs/sdAbs/nanobodies) as research tools, diagnostics, and therapeutics. Commercially, several patents were granted to pioneering research groups in Belgium and the Netherl...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yazar: Mehdi Arbabi-Ghahroudi
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: MDPI AG 2022-04-01
Seri Bilgileri:International Journal of Molecular Sciences
Konular:
camelid heavy-chain antibody
VHH
single-domain antibody
nanobody
caplacizumab
biotherapeutics
Online Erişim:https://www.mdpi.com/1422-0067/23/9/5009
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller